NL-OMON23876已完成不适用
Terlipressin versus albumin in the prevention of paracentesis associated adverse events in patients with cirrhosis and tense ascites. A multicenter randomised controlled trial.
Foundation for Liver Research (SLO)Erasmus MCc/o department of hepatology and gastroenterology,room Ca 326Dr. Molewaterplein 403015 GD Rotterdamtel (010) 463 59420 个研究点目标入组 84 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 84
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Cirrhosis with tense ascites requiring therapeutic paracentesis;
- •2. Age 18-70;
排除标准
- •1. Hypertension treated with medication;
- •2. History of cardiac or coronary disease;
研究者
相似试验
已完成
不适用
Terlipressin versus albumin in the prevention of paracentesis-associated adverse events in patients with cirrhosis and tense ascitesCirrhosis of the liver/ascitesDigestive SystemFibrosis and cirrhosis of liverISRCTN36383299Foundation for Liver and Gastrointestinal Research (SLO) (Netherlands)84
已完成
不适用
Efficacy of early terlipressin (drug) in ACLF (Liver Disease)CTRI/2020/06/026006Institute of Liver and Biliary Sciences70
Unknown
2 期
Terlipressin Given As I.V. Boluses Versus Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal SyndromeType 1 Hepatorenal SyndromeCirrhosisNCT00742690University of Padova70
终止
2 期
Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal SyndromeCirrhosisHepatorenal SyndromeNCT00742339University of Padova49
Unknown
4 期
The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial PressureHepatorenal SyndromeNCT02489864Sun Yat-sen University30